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Runx2 and Cbfβ are essential for skeletal development during the embryonic stage. Runx2 has two isoforms with different N-termini. We
examined the functions of the Runx2 isoforms and Cbfβ in postnatal bone development. On luciferase and electrophoretic mobility shift assays,
Runx2-I was less active than Runx2-II in the absence of Cbfb, but the two Runx2 isoforms had similar activity levels in the presence of Cbfb. We
generated Runx2-I transgenic mice under the control of Col1a1 promoter and Runx2-I/Cbfb and Runx2-II/Cbfb double transgenic mice. Runx2-I
transgenic mice showed less severe osteopenia and fragility than Runx2-II transgenic mice due to milder inhibition of both osteoblast maturation
and transition to osteocytes, even though the former mice showed higher transgene expression. However, Runx2-I/Cbfb and Runx2-II/Cbfb double
transgenic mice had enhanced inhibition of osteoblast maturation, resulting in similar severity of osteopenia and fragility, although the latter mice
had less osteocytes. These findings indicate that (1) Runx2-II more strongly inhibits osteoblast maturation and transition to osteocytes than Runx2-
I; (2) Cbfβ regulates Runx2 function isoform-dependently; and (3) Runx2-I activity is highly dependent on Cbfβ. These findings demonstrate that
Runx2 isoforms exert their functions through at least partly different mechanisms and Cbfβ regulates bone development by regulating Runx2
function isoform-dependently.
© 2006 Elsevier Inc. All rights reserved.Keywords: Runx2/Cbfa1; Cbfβ; osteoblast; osteocyte; osteocalcinIntroduction
Runx2 (runt-related transcription factor 2)/Cbfa1 (core-
binding factor α1)/Pebp2αA (polyoma enhancer-binding pro-
tein 2αA), which belongs to the Runx family, is an essential
transcription factor for osteoblast differentiation and plays an
important role in chondrocyte maturation (Komori, 2005).
Runx2-deficient (Runx2−/−) mice completely lack osteoblasts
and Runx2−/− cells have the potential to differentiate into both
chondrocytes and adipocytes, indicating that Runx2 plays an⁎ Corresponding author. Fax: +81 95 849 7633.
E-mail address: komorit@net.nagasaki-u.ac.jp (T. Komori).
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doi:10.1016/j.ydbio.2006.03.039essential role in the commitment of mesenchymal cells into the
osteoblast lineage (Komori et al., 1997; Otto et al., 1997;
Kobayashi et al., 2000). Runx2 is also involved in osteoclast
differentiation by inducing RANKL expression and inhibiting
OPG expression (Enomoto et al., 2003). Therefore, Runx2 is a
multifunctional transcription factor in skeletal development
(Komori, 2005).
Runx2 has at least two isoforms with different N-terminal
sequences (Ogawa et al., 1993a; Stewart et al., 1997). One pro-
duct starts with a sequence (MRIPVD) encoded by exon 2
(hereafter referred to as Runx2-I), whereas the other product
starts with the sequence MASNS, which contains the sequence
encoded by exon 1 spliced to the aspartic acid residue at position
6 of the sequence encoded by exon 2 (hereafter referred to as
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sion indicate that two promoters, located in the 5′ region of exon
1 (distal promoter) and in intron 1 (proximal promoter), regulate
Runx2 expression (Fujiwara et al., 1999; Lengner et al., 2002).
Although both isoforms are expressed in osteoblasts as well as
chondrocytes, Runx2-I is also expressed in osteoprogenitors and
other mesenchymal tissues (Enomoto et al., 2000; Banerjee et
al., 2001; Park et al., 2001; Choi et al., 2002). The two isoforms
of Runx2 with different N-terminal domains showed different
levels of transcriptional activation of their target genes in vitro
(Harada et al., 1999; Xiao et al., 1999). The two isoforms of
Runx2 exerted a similar function in chondrocytes, although
Runx2-II seemed to have stronger activity than Runx2-I (Ueta et
al., 2001). Runx2-II-specific knockout mice were recently gene-
rated. Both intramembranous and endochondral ossification
occur less effectively in Runx2-II−/− mice than in wild-type
mice, leading to osteopenia (Xiao et al., 2004, 2005). These
findings indicate that both Runx2-I and Runx2-II are required
for osteoblast differentiation and bone formation. Therefore, the
differences in the functions of the two isoforms in osteoblasts
need to be further investigated.
Runx2 has been shown to induce the expression of bone
matrix protein genes including Col1a1, osteopontin, bone sialo-
protein, osteocalcin, and fibronectin (Ducy et al., 1997; Harada
et al., 1999; Ducy et al., 1999; Lee et al., 2000), suggesting that
Runx2 plays a major role in the production of bone matrix
proteins in osteoblasts. However, transgenic mice that over-
express Runx2-II under the control of Col1a1 promoter, which
directs transgene expression in immature and mature osteo-
blasts, showed osteopenia with multiple fractures (Liu et al.,
2001; Geoffroy et al., 2002). The osteoblasts of these mice had
reduced expression of the Col1a1, alkaline phosphatase, osteo-
calcin, and MMP13 genes, which are normally upregulated in
mature osteoblasts, indicating that osteoblast maturation was
inhibited. Therefore, the function of Runx2 in postnatal bone
development is still controversial and remains to be clarified.
Cbfβ (core-binding factor β) is a cotranscription factor that
does not directly bind with DNA and enhances the in vitro DNA
binding of the runt protein, which is a DNA-binding domain
common to the Runx family (Ogawa et al., 1993b). Cbfb is
involved in the chromosomal translocation, inv16, in acute
leukemia, and Cbfβ is essential for Runx1-dependent hemato-
poiesis in the fetal liver (Sasaki et al., 1996, Wang et al., 1996).
Further, it has been shown that Cbfβ is required for Runx2-
dependent skeletal development during embryogenesis (Kundu
et al., 2002; Miller et al., 2002; Yoshida et al., 2002). However,
the function of Cbfβ in postnatal bone development remains to
be clarified.
To investigate the functions of Runx2 isoforms and Cbfβ in
postnatal bone development, we performed in vitro and in vivo
studies. Reporter assay and electrophoretic mobility shift assay
(EMSA) showed that the transcriptional and DNA-binding
activities of Runx2-I are more dependent on Cbfβ than those of
Runx2-II. In in vivo studies, we generated transgenic mice that
overexpress Runx2-I under the control of Col1a1 promoter, and
Runx2-I/Cbfb and Runx2-II/Cbfb double transgenic mice by
mating each Runx2 transgenic mouse line with transgenic micethat overexpress Cbfb under the control of cytomegalovirus
(CMV) promoter. Although the level of the expressed transgene
in Runx2-I transgenic mice was several times higher than that in
Runx2-II transgenic mice that had been previously reported (Liu
et al., 2001), the former mice showed less severe osteopenia
than Runx2-II transgenic mice due to milder inhibition of
osteoblast maturation. In contrast, Runx2-I/Cbfb and Runx2-II/
Cbfb double transgenic mice showed similar phenotypes with
severe osteopenia and multiple fractures due to marked inhibi-
tion of osteoblast maturation. During the transition of osteo-
blasts to osteocytes, however, Runx2-II was a stronger inhibitor
than Runx2-I, regardless of the dosage of Cbfβ. These findings
indicate that both Runx2 isoforms keep osteoblasts in an imma-
ture stage and inhibit the transition of osteoblasts to osteocytes
through at least partly different mechanisms, and that Cbfβ
enhances their activities isoform-dependently.
Results
Transcriptional and DNA-binding activities of Runx2-I were
more dependent on Cbfb than those of Runx2-II
The ability of transcriptional activation by Runx2-I and
Runx2-II was examined in Cbfb−/− calvarial cells using the
osteocalcin promoter (Fig. 1A). In the absence of Cbfb, there
was weak transcriptional activation by Runx2-I or Runx2-II,
with Runx2-II having higher activity than Runx2-I. However,
introduction of Cbfb more strongly enhanced transcriptional
activation by Runx2-I than that by Runx2-II. The DNA-binding
activity of Runx2-I and Runx2-II was examined by EMSA (Fig.
1B). A Runx2-I- or Runx2-II-expressing vector was transfected
into Cbfb−/− calvarial cells with or without Cbfb-expressing
vector, and the DNA-binding activity of Runx2-I and Runx2-II
was examined using Runx2-binding oligonucleotides. Both
Runx2-I and Runx2-II showed no apparent DNA binding in the
absence of Cbfb; however, the presence of Cbfb enhanced the
DNA binding of both Runx2 isoforms, although it more strongly
enhanced DNA binding of Runx2-I. Similarities of the protein
levels of Runx2 or Cbfβ in the nuclear extracts were confirmed
by Western blot analysis (Fig. 1C). These findings indicate that
the DNA-binding activity of Runx2-I is more dependent on
Cbfβ than that of Runx2-II, and that Runx2-I has at least a
similar ability for transcriptional activation as Runx2-II in the
presence of a sufficient amount of Cbfβ.
Transgenic mice that overexpress Runx2-I under the control of
Col1a1 promoter showed mild osteopenia
To investigate the function of Runx2-I in postnatal bone
development, we generated transgenic mice that overexpress
Runx2-I in osteoblasts under the control of the Col1a1 promoter
(Fig. 2A). We obtained 25 F0 transgenic mice in which expres-
sion of the transgenewas detected byNorthern blot analysis. One
of the F0 mice was mated with B6C3H/F1 mice to establish a line
of transgenicmice and the other F0micewere analyzed at 6 weeks
of age. In these F0 mice and the established line, the trabecular
bone volume and cortical thickness decreased as the expression
Fig. 1. Luciferase assay and EMSA. (A) Transcriptional activities of Runx2-I and Runx2-II were examined inCbfb−/− calvarial cells using osteocalcin promoter. Mouse
osteocalcin promoter construct p147mOG2-luc (100ng) and Runx2-I or Runx2-II (100ng) with or without Cbfb (100ng) were transfected into Cbfb−/− calvarial cells,
and then luciferase activity was measured as described in the Materials and methods. Data are represented as mean ± SEM of 4 wells. Four independent experiments
were performed, and representative data are shown. *P < 0.005 vs. pSG5 alone. (B) DNA-binding activity of Runx2-I and Runx2-II was examined by EMSA. Runx2-I-
or Runx2-II-expressing vector was transfected into Cbfb−/− calvarial cells with or without Cbfb-expressing vector, and the DNA-binding activity of Runx2-I and
Runx2-II was examined using OSE2 oligonucleotides, which include the Runx2 recognition sequence. Nuclear extracts were loaded as indicated. Cbfβ (lane 1),
Runx2-I (lane 2), or Runx2-II (lane 3) alone could not form DNA-binding complexes, whereas the formation of specific DNA-binding complexes was observed when
both Runx2 and Cbfbwere cotransfected (lanes 4 and 5). The bands of DNA-binding complexes were stronger in Runx2-I (lanes 4 and 6) than in Runx2-II (lanes 5 and
7) in the presence of Cbfβ. Unlabeled OSE2 oligonucleotides competed for binding with Runx2-I and Runx2-II (lanes 8 and 12, ×100), whereas the mutated
oligonucleotides did not (lanes 9 and 13, ×100). Addition of antibody against Runx2 or Cbfβ supershifted the specific bands or prevented the formation of the specific
Runx2-Cbfβ-DNA complexes (lanes 10, 11, 14, and 15). Arrow indicates the specific bands, asterisk indicates the super-shifted complexes, and arrowhead indicates
nonspecific bands seen in all lanes. (C) The levels of Runx2 and Cbfβ protein in nuclear extracts from cells that had been transfected with Runx2-I, Runx2-II, Runx2-I
plus Cbfb, or Runx2-II plus Cbfb were examined by Western blot analysis using monoclonal anti-Runx2 and anti-Cbfβ antibodies.
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high transgene expression suffered fractures as observed on X-
ray and histological analyses (Figs. 2B and 3A–H, K, data notshown). Although the osteocytes in the cortical bone were
regularly oriented in F0 transgenic mice with low transgene
expression, there were fewer osteocytes in the cortical bone and
Fig. 2. Generation of Runx2-I transgenic mice. (A) Diagram of the DNA construct used to generate transgenic mice that overexpress Runx2-I under the control of the
Col1a1 promoter. (B) Northern blot analysis of the transgene and X-ray analysis. The expression level of the transgene was examined by Northern blot analysis using
total RNA from limb long bones of two F0 (F0 low and F0 high) Runx2-I transgenic mice and the lines of Runx2-I (line) and Runx2-II transgenic mice at 6 weeks of age.
Ten micrograms of RNAwas loaded and hybridized with 32P-labeled cDNA probes for runt and GAPDH. GAPDH was used as an internal control. X-ray analysis was
performed at 6 weeks of age. The translucency of the femurs increased as the expression level of the transgene increased among Runx2-I transgenic mice, and F0 mice
with high transgene expression suffered multiple fractures. Runx2-II transgenic mice were severely osteopenic, even though there was low expression of the transgene.
A large fracture is seen in the F0 mouse with high expression, and two microfractures are seen in the Runx2-II transgenic mouse. (C) Comparison of endogenous Runx2
mRNA expression in Runx2-I and Runx2-II transgenic mice by Northern blot analysis. RNAwas extracted from limb long bones of wild-type (wt) and Runx2-I (I) and
Runx2-II (II) transgenic newborn mice. Three micrograms of poly-A RNAwas loaded and hybridized with 32P-labeled cDNA probes for runt and GAPDH. GAPDH
was used as an internal control. Wild-type and Runx2-I and Runx2-II transgenic mice expressed similar levels of endogenous Runx2 mRNA (arrowhead). Arrow
indicates bands of the transgene.
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irregular manner in the established line and in F0 transgenic mice
with high transgene expression (Figs. 3A–H, L, and data not
shown). The relatively round shape and irregular orientation of
the osteocytes suggest that the osteocytes and bone are immature
inRunx2-I transgenicmice. Following is a detailed description of
the phenotype of the established line. Although the expression
level of the transgene in the established transgenic line was
several times higher than that in Runx2-II transgenic mice that
had been previously reported (Liu et al., 2001), the degree of
osteopenic change and the degree of reduction in the number of
osteocytes were much milder in Runx2-I transgenic mice (Figs.
2B and 3F, J, L). pQCTanalysis showed that the cortical mineral
density and cortical thickness were reduced in Runx2-I tran-
sgenic mice compared with wild-type mice at 18 weeks of age
(Figs. 4A–C). The endosteal circumference was enlarged in the
transgenic mice compared with wild-type mice, indicating that
osteolysis was relatively enhanced compared with bone for-
mation in the endosteum (Fig. 4D). However, the degree of thereductions in cortical mineral density and cortical thickness and
the degree of expansion of the bone marrow cavity were milder
in Runx2-I transgenic mice than in Runx2-II transgenic mice
(Fig. 4). The expression of endogenous Runx2 was not affected
by expression of the transgene in both Runx2-I and Runx2-II
transgenic mice (Fig. 2C). These findings indicate that Runx2-I
transgenic mice showmilder osteopenia and milder inhibition of
the transition to osteocytes than Runx2-II transgenic mice.
Osteoblast maturation was inhibited in Runx2-I transgenic
mice
To investigate the maturational stage of osteoblasts, we ana-
lyzed Col1a1, osteopontin, and osteocalcin expression by
Northern blot and in situ hybridization analyses (Fig. 5).
Col1a1 is expressed in immature and mature osteoblasts, osteo-
pontin is expressed in relatively immature osteoblasts, and
osteocalcin is expressed in mature osteoblasts. The level of
Col1a1 expression in Runx2-I transgenic mice was similar to
Fig. 3. Histological analysis of the tibiae of Runx2-I and Runx2-II transgenic
mice at 6 weeks of age. Sections from tibiae were stained with H–E. (A and B)
Wild-type mice; (C and D) F0 Runx2-I transgenic mice with low transgene
expression; (E and F) Runx2-I transgenic line; (G and H) F0 Runx2-I transgenic
mice with high transgene expression; (I and J) Runx2-II transgenic line. (B, D, F,
H, and J) Cortical bone in the diaphyses. (K and L) Trabecular bone volume
(bone volume divided by tissue volume, BV/TV) (K) and osteocyte number (L)
in wild-type mice (wt), F0 Runx2-I transgenic mice with low or high transgene
expression (F0 low and F0 high), Runx2-I transgenic line (line), and Runx2-II
transgenic mice (II). The trabecular bone volume, cortical thickness, and
osteocyte number decreased among Runx2-I transgenic mice as the expression
level of the transgene increased (A–H, K, L). In Runx2-II transgenic mice, the
trabecular bone volume and cortical thickness were decreased and the number of
osteocytes was severely reduced in the bones (I, J, K, L). Scale bars: A, C, E, G,
I = 500 μm; B, D, F, H, J = 100 μm.
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was increased and the level of osteocalcin expression was
severely reduced in the transgenic mice (Fig. 5). As osteoblast
number was similar between wild-type and Runx2-I transgenic
mice (Fig. 8B), these data show that osteopontin expression was
upregulated and osteocalcin expression was severely down-
regulated in individual osteoblast of Runx2-I transgenic mice,
indicating that osteoblast maturation was inhibited in Runx2-I
transgenic mice.
Both Runx2-I/Cbfb and Runx2-II/Cbfb double transgenic mice
showed severe osteopenia with multiple fractures
To investigate whether Cbfβ is required for the activity of
Runx2 isoforms in postnatal bone development, we first gene-
rated transgenic mice that overexpress Cbfb under the control of
the CMV promoter (Figs. 6A and B). Although the Cbfb trans-
gene was ubiquitously expressed in the transgenic mice, there
were no apparent abnormalities on histological analysis of
various tissues including the brain, heart, lung, liver, kidney,
muscle, and skin (data not shown). The skeleton also developed
normally and there were no abnormalities on X-ray, pQCT,
histological, and histomorphometrical analyses (Figs. 6–8). We
mated Cbfb transgenic mice with transgenic mice that over-
express each Runx2 isoform and generated Runx2-I/Cbfb and
Runx2-II/Cbfb double transgenic mice. Although Runx2-I trans-
genic mice were mildly osteopenic, Runx2-I/Cbfb transgenic
mice showed severe osteopenia with multiple fractures (Fig.
6C). Runx2-II transgenic mice were osteopenic and suffered
multiple fractures, and the fractures were more severe in Runx2-
II/Cbfb transgenic mice than Runx2-II transgenic mice (Liu et
al., 2001) (Figs. 2B and 6C). On the protein level, Runx2-I
transgenic mice expressed a higher level of Runx2 than Runx2-II
transgenic mice, and the protein levels of Runx2 in Runx2-I/
Cbfb and Runx2-II/Cbfb double transgenic mice did not differ
from that in the respective single Runx2 transgenic mice, ruling
out the possibility that Cbfβ differentially stabilizes the two
Runx2 isoforms (Fig. 6D).
Trabecular bone volume, cortical density, and cortical
thickness were severely reduced in both Runx2-I/Cbfb and
Runx2-II/Cbfb double transgenic mice
We compared the results of pQCT and histomorphome-
trical analyses of femurs of Runx2-I transgenic mice, Runx2-II
transgenic mice, Runx2-I/Cbfb transgenic mice, and Runx2-II/
Cbfb transgenic mice at 6 weeks of age (Figs. 7 and 8). On
pQCT analysis, cortical density and cortical thickness were
further reduced in Runx2-I/Cbfb transgenic mice compared
with Runx2-I transgenic mice, whereas they were similar bet-
ween Runx2-II and Runx2-II/Cbfb transgenic mice (Fig. 7),
indicating that addition of the Cbfb transgene significantly
worsened the phenotype in the cortical bone in Runx2-I trans-
genic mice.
On histomorphometrical analysis of the secondary spongiosa,
the bone volume was significantly reduced in both Runx2-I and
Runx2-II transgenic mice (Fig. 8A). As the bone volume in three
Fig. 4. pQCT analysis of Runx2-I and Runx2-II transgenic mice. The diaphyses of femurs from wild-type and transgenic mice at 18 weeks of age were analyzed by
pQCT. (A) pQCT images from wild-type (wt), Runx2-I transgenic, and Runx2-II transgenic mice. (B–D) The cortical density (B), cortical thickness (C), and endosteal
circumference (D) were measured in wild-type (wt, open bars), Runx2-I transgenic (I, closed bars), and Runx2-II transgenic (II, dotted bars) mice. Data are represented
as mean ± SEM of 11 mice. *P < 0.05, **P < 0.005 compared with wild-type mice as determined by one-way ANOVA. The reductions in cortical density and thickness
and the enlargement of endosteal circumference in Runx2-I transgenic mice are milder than those in Runx2-II transgenic mice.
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II/Cbfb transgenic mice was less than 1%, these 6 mice were
excluded from the histomorphometrical analysis because it was
not possible to acquire reliable data in the other parameters. If
they were included, the bone volume was severely further
reduced in both Runx2-I/Cbfb and Runx2-II/Cbfb transgenic
mice at a similar level (Runx2-I vs. Runx2-I/Cbfb, 5.39 ± 0.5%
and 1.68 ± 0.6%, P < 0.01; Runx2-II vs. Runx2-II/Cbfb,
4.64 ± 0.6% and 1.49 ± 0.7%, P < 0.01). Compared with the
wild-type mice, the osteoblast number (N.Ob/B.Pm) was in-
creased in Runx2-II but not in Runx2-I transgenic mice, whereas
it was increased in Runx2-I/Cbfb transgenic mice (Fig. 8B). In
contrast, bone matrix production was severely impaired in all of
the transgenic mouse lines except the Cbfb transgenic mice, as
shown by the decreased thickness of newly deposited matrix
(osteoid thickness; O.Th) (Fig. 8C). The osteocyte number in the
cortical bone (osteocyte/Ar) was reduced in all of the Runx2 and
Runx2/Cbfb transgenic mice, although it was more severely
reduced in the Runx2-II and Runx2-II/Cbfb transgenic mice (Fig.
8D). There were no significant differences in the osteoclast
number (Mu.N.Oc/B.Pm) among the transgenic mouse lines and
the wild-type mice (Fig. 8E). To perform kinetic analysis of bone
formation, we injected calcein twice at 5 days and at 1 day before
sacrifice at 6 weeks of age. The distance between the double
labeling (mineral apposition rate; MAR) and the bone formation
rate (BFR/BS) were reduced in Runx2-II transgenic mice more
so than in Runx2-I transgenic mice in comparison with wild-type
mice (Figs. 8F and G).
These findings indicate that the reduction in bone formation,
whichwas caused by impairment of osteoblast function and not a
decrease in osteoblast number, led to a decrease in bone volume
in both Runx2-I and Runx2-II transgenic mice, and that Runx2-IImore severely inhibits the transition of osteoblasts to osteocytes.
These findings also suggest that the further reduction of bone
volume in both Runx2-I/Cbfb and Runx2-II/Cbfb transgenic
mice was caused by worsened osteoblast function because the
number of osteoblasts, but not osteoclasts, was increased. As a
further reduction in bone formation rate was not observed in
either of the Runx2/Cbfb transgenic mouse lines, however, a
major cause of the severe reduction in bone volume would be the
extremely immature quality of the bone that was formed by the
immature osteoblasts, which would facilitate bone resorption, as
described below.
Osteoblast maturation was severely inhibited in both
Runx2-I/Cbfb and Runx2-II/Cbfb transgenic mice
We compared the quality of the bone by polarized micro-
scopy and the maturational stage of osteoblasts by in situ hy-
bridization using Col1a1, osteopontin, and osteocalcin probes
among wild-type mice and Runx2-I, Runx2-II, Runx2-I/Cbfb,
and Runx2-II/Cbfb transgenic mice (Fig. 9). In the wild-type
mice, the cortical bone was composed of mature lamellar bone
with highly ordered, parallel collagen fibers (Fig. 9A). However,
in all of the transgenic mouse lines, the cortical bone was com-
posed of immature bone, which is generally described as woven
bone, in which collagen fibers ran in all directions. The cortical
bone of Runx2-II transgenic mice seemed to be more immature
than that of Runx2-I transgenic mice, and addition of the Cbfb
transgene seemed to further inhibit maturation (Fig. 9A). On in
situ hybridization, mild reduction of Col1a1 expression, up-
regulation of osteopontin expression, and severe reduction of
osteocalcin expression were observed in the cortical bones of all
of the Runx2 and Runx2/Cbfb transgenic mice compared with
Fig. 5. Analysis of the expression of bone matrix protein genes. (A) RNAwas extracted from limb long bones at 6 weeks of age for Northern blot analysis. Fifteen
micrograms of total RNA was loaded and hybridized with probes for Col1a1, osteopontin, osteocalcin, and GAPDH. GAPDH was used as an internal control.
Representative data from four independent samples are shown. (B) Sections of tibiae from wild-type and transgenic mice at 8 weeks of age were subjected to in situ
hybridization using Col1a1, osteopontin, and osteocalcin probes. The number of osteopontin-positive cells was increased but the number of osteocalcin-positive cells
was decreased in Runx2-I transgenic mice compared with wild-type mice.
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deposition was increased in all of the transgenic mice (data not
shown). In accordance with the increased deposition of osteo-
pontin, which contains the small cell attachment motif Arg-Gly-
Asp recognized by integrins and promotes the attachment of
osteoclasts to the extracellular matrix, TRAP-positive osteo-
clasts were frequently observed in all Runx2 and Runx2/Cbfb
transgenic cortical bones but rarely in wild-type cortical bones
(Fig. 9E). Invasion of bone marrow into the cortical bone wasapparently increased in Runx2-II transgenic mice and it was
further enhanced in both Runx2-I/Cbfb and Runx2-II/Cbfb
transgenic mice, showing the appearance of trabecular bone.
According to the increase in bone surface, there was appa-
rently an increased number of osteoblasts in the cortical bone
(Fig. 9C).
On real-time reverse transcription (RT)-polymerase chain
reaction (PCR) analysis, osteopontin expression was increased
but osteocalcin expression was severely reduced in all of the
Fig. 6. Generation of Cbfb transgenic mice and X-ray analysis of Runx2-I/Cbfb and Runx2-II/Cbfb double transgenic mice. (A) Diagram of the DNA construct for
generation of transgenic mice that overexpress Cbfb under the control of CMV promoter. (B) Northern blot analysis of the expression of the Cbfb transgene. RNAwas
extracted from long bones of wild-type (wt) and Cbfb transgenic (Cbfb) mice. Ten micrograms of RNA was loaded. (C) X-ray analysis of wild-type (wt), Cbfb
transgenic, Runx2-I/Cbfb transgenic, and Runx2-II/Cbfb transgenic mice at 6 weeks of age. Lower panels show femurs. Both lines of Runx2/Cbfb double transgenic
mice show severe osteopenia and fractures. (D) Immunoblots of Runx2. Western blot analysis was performed using whole cell lysate of calvarial bone from wild-type
(wt), Runx2-I transgenic (I), Runx2-II transgenic (II), Runx2-I/Cbfb transgenic (I/b), and Runx2-II/Cbfb transgenic (II/b) mice at 2 weeks of age. Actin was used as an
internal control.
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Osteocalcin expression was significantly reduced in Runx2-I/
Cbfb transgenic mice and marginally reduced in Runx2-II/Cbfb
transgenic mice compared with the respective single transgenic
mice. As the number of osteoblasts in both the trabecular bone
and cortical bone of Runx2-II transgenic mice was much higher
than that in Runx2-I transgenic mice (Figs. 8B and 9C), the level
of osteocalcin expression in individual osteoblasts should be
lower in Runx2-II transgenic mice. These findings indicate that
osteoblast maturation was more severely inhibited in Runx2-II
transgenic mice than in Runx2-I transgenic mice, and that Cbfβ
enhanced Runx2-I-mediated inhibition more strongly than
Runx2-II-mediated inhibition.As there was an increased number of osteoclasts in the cor-
tical bone in all Runx2 and Runx2/Cbfb transgenic mice (Fig.
9E), we examined RANKL and OPG expression by real-time
RT-PCR (Fig. 10A). RANKL expression was decreased in
Runx2-II transgenic mice, and OPG expression was decreased
in Runx2-II and Runx2-II/Cbfb transgenic mice. The increased
ratio of RANKL to OPG expression in Runx2-II/Cbfb transgenic
mice may partly contribute to the increased number of osteo-
clasts in the cortical bone.
In accordance with inhibition of osteoblast maturation, osteo-
blast proliferation, which was examined by BrdU labeling, was
enhanced in all of the transgenic mouse lines except Cbfb trans-
genic mice (Fig. 10B). However, the frequency of apoptosis,
Fig. 7. pQCT analyses. pQCT analyses were performed using femurs from wild-type (wt), Cbfb transgenic (b), Runx2-I transgenic (I), Runx2-II transgenic (II), Runx2-
I/Cbfb transgenic (I/b), and Runx2-II/Cbfb transgenic (II/b) mice at 6 weeks of age. pQCT images (A), cortical density (B), and cortical thickness (C) at mid-diaphyses
are shown. Scale bar, 1 mm. Mineral densities are shown as different colors according to the standard mineral density gradients (A). Error bars show means ± SEM
(n = 3–5). *P < 0.05, **P < 0.005 vs. wild-type mice, as determined by one-way ANOVA.
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the wild-type and all of the transgenic mouse lines (Fig. 10C).
Discussion
Osteoblast maturation and transition to osteocytes were
mildly inhibited in Runx2-I transgenic mice and strongly inhi-
bited in Runx2-II transgenic mice, leading to mild or severe
osteopenia, respectively. However, addition of the Cbfb trans-
gene enhanced the inhibition of osteoblast maturation by Runx2-
I more strongly than that by Runx2-II, leading to severe osteo-
penia with multiple fractures in both lines of Runx2/Cbfb double
transgenic mice. Runx2-II had stronger ability of inhibition of
the transition to osteocytes than Runx2-I, irrespective of the
dosage of Cbfβ. In the presence of a sufficient amount of Cbfβ,
Runx2-I exerted at least similar abilities in transcriptional acti-
vation and DNA binding as Runx2-II. Therefore, Runx2-II more
strongly inhibits osteoblast maturation and transition to osteo-
cytes than Runx2-I, but Cbfβ strongly enhances the function of
Runx2-I.
Difference in the inhibition of osteoblast maturation between
Runx2-I and Runx2-II transgenic mice
After multipotent mesenchymal cells commit to the osteo-
blastic lineage, the cells become immature osteoblasts, strongly
expressing osteopontin, and then they become mature osteo-
blasts, strongly expressing osteocalcin, and finally the mature
osteoblasts are embedded in the bone matrix to become osteo-
cytes (Aubin and Triffitt, 2002). Runx2 is essential for
commitment of mesenchymal cells into the osteoblastic lineage
because Runx2−/− mice completely lack osteoblasts (Komori et
al., 1997; Otto et al., 1997). However, the function of Runx2
after commitment of mesenchymal cells into the osteoblastic
lineage remains to be clarified. The DNA-binding sites of Runx2in major bone matrix protein genes including the Col1a1, osteo-
pontin, bone sialoprotein, and osteocalcin genes have been
identified, and Runx2 induced the expression of these genes or
activated their promoters in vitro (Ducy and Karsenty, 1995;
Ducy et al., 1997; Geoffroy et al., 1995; Merriman et al., 1995;
Banerjee et al., 1996, 1997; Sato et al., 1998; Thirunavukkarasu
et al., 1998; Harada et al., 1999; Javed et al., 1999; Xiao et al.,
1999; Alliston et al., 2001; Kern et al., 2001; Javed et al., 2001;
Zaidi et al., 2001). However, overexpression of either Runx2-I or
Runx2-II in osteoblasts inhibited osteoblast maturation and
severely reduced osteocalcin expression (Liu et al., 2001) (Figs.
5, 9D, and 10A), although in vitro studies showed that Runx2
strongly induced osteocalcin expression in the mouse embryonic
fibroblast cell line C3H10T1/2 (Ducy et al., 1997, Harada et al.,
1999). Moreover, overexpression of Cbfb further enhanced the
inhibition of osteoblast maturation and further reduced osteo-
calcin expression in the individual osteoblast (Figs. 8B, 9D,
10A), although Cbfβ strongly enhanced osteocalcin promoter
activity (Harada et al., 1999). Therefore, our findings combined
with the previous in vitro data indicate that both Runx2-I and
Runx2-II together with Cbfβ trigger the expression of major
bone matrix protein genes at an early stage of osteoblast diffe-
rentiation, leading to the cells acquiring the osteoblastic phe-
notype but keeping the osteoblastic cells in an immature stage.
Therefore, both Runx2 isoforms play an important role in main-
taining a supply of immature osteoblasts.
In accordance with the stronger inhibition of osteoblast ma-
turation by Runx2-II than by Runx2-I, Runx2-II more severely
inhibited the transition to osteocytes than Runx2-I. Although
both Runx2-I/Cbfb and Runx2-II/Cbfb transgenic mice showed
similar reduction in osteocalcin expression, Runx2-II/Cbfb trans-
genic mice showed stronger inhibition of the transition to osteo-
cytes than Runx2-I/Cbfb transgenic mice. Therefore, it seems that
Runx2-II inhibits the transition to osteocytes not only by inhi-
biting osteoblast maturation but also by a unique unknown
Fig. 8. Bone histomorphometric analysis. Trabecular bone volume (bone volume divided by tissue volume, BV/TV) (A), osteoblast number (N.Ob) (B), osteoid
thickness (O.Th) (C), osteocyte number (D), osteoclast number (Mu.N.Oc) (E), mineral apposition rate (MAR) (F), and bone forming rate (BFR) (G) are compared
among wild-type (wt),Cbfb transgenic (b), Runx2-I transgenic (I), Runx2-II transgenic (II), Runx2-I/Cbfb transgenic (I/b), and Runx2-II/Cbfb transgenic (II/b) mice at 6
weeks of age. The analyses were done at the secondary spongiosa using the distal part of femurs. Bars show means ± SEM (n = 4–5). *P < 0.05 and **P < 0.01 vs.
wild-type mice and #P < 0.05 and ##P < 0.01 vs. Cbfb transgenic mice, as determined by one-way ANOVA.
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ficantly decrease the osteocyte number, Cbfβ seems to have en-
hanced the inhibition of the transition to osteocytes because the
numbers of osteoblasts in the trabecular and cortical bones were
increased in both lines of Runx2/Cbfb double transgenic mice.
Difference in osteoblast number between Runx2-I and Runx2-II
transgenic mice
In accordance with the inhibition of osteoblast maturation,
osteoblast proliferation was increased in both Runx2-I and Runx2-II transgenic mice (Fig. 10B). However, the osteoblast number was
increased inRunx2-II transgenicmice but not inRunx2-I transgenic
mice, even though there were similar frequencies of TUNEL-
positive osteoblastic cells in the two lines of Runx2 transgenic mice
(Figs. 8B and 10C). Accumulation of immature osteoblasts may
inhibit the commitment of multipotent mesenchymal cells into the
osteoblastic lineage because the number of adipocytes in bone
marrows was increased as the inhibition of osteoblast maturation
was enhanced (N. K. and T. K., unpublished observations). The
increased osteoblast number in Runx2-II transgenic mice would be
caused by severe inhibition of the transition to osteocytes (Figs. 8B
Fig. 9. Histological analysis. Decalcified sections of tibiae from wild-type (wt), Runx2-I transgenic, Runx2-II transgenic, Runx2-I/Cbfb transgenic, and Runx2-II/Cbfb
transgenic mice at 4 weeks of age were examined by polarized microscopy (A) and used for in situ hybridization usingCol1a1 (B), osteopontin (C), and osteocalcin (D)
probes. Undecalcified sections were stained for TRAP (E). TRAP-positive cells are indicated by arrowheads. Cortical bones at diaphyses are shown. Scale bar, 100 μm.
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promote osteoblast differentiation at the early stage when the 2.3-
kb Col1a1 promoter starts to function, but the two isoforms seem
to have similar capacity of promotion if a sufficient amount of
Cbfβ is present because the osteoblast number was increased in
Runx2-I/Cbfb transgenic mice (Fig. 8B).
Different degrees of dependence of the functions of Runx2
isoforms on Cbfβ
One of the important roles of Cbfβ is inhibition of proteolytic
degradation of Runx1 (Huang et al., 2001). However, the sta-
bility of both Runx2 isoform proteins was not affected by the
amount of Cbfβ in vivo (Fig. 6D), and this is compatible with the
previous finding that Runx2 was stable in Cbfb−/− mice that had
been rescued by the Cbfb transgene driven by the Gata1 promo-
ter (Yoshida et al., 2002). Therefore, Cbfβ enhances the function
of both Runx2 isoforms through a mechanism other than stabi-
lizing each isoform. Runx2-I was less active than Runx2-II, but
Cbfβ more strongly enhanced the function of Runx2-I than
Runx2-II in vivo. In accordance with the in vivo findings, the
EMSA and reporter assay showed that the Runx2-I activities of
DNA binding and transcriptional activation are highly depen-dent on Cbfβ (Fig. 1). As the band for Runx2-I-Cbfβ-DNA
complexes was always stronger than that for Runx2-II-Cbfβ-
DNA complexes on EMSA, however, a difference in the affinity
of the two Runx2 isoforms for Cbfβ does not explain the high
dependence of Runx2-I on Cbfβ. As osteoblast differentiation
occurred at a limited level in Cbfb−/−mice that had been rescued
by the Cbfb transgene driven by the Gata1 promoter (Yoshida et
al., 2002), Runx2-II, but not Runx2-I, seems to mainly contri-
bute to osteoblast differentiation in the absence of Cbfb. There-
fore, these findings indicate that the N-terminal amino acids of
Runx2, which differ in the two Runx2 isoforms, determine the
absolute requirement of Cbfβ and suggest that unknown
proteins may partly substitute for Cbfβ in the DNA binding of
and transcriptional activation by Runx2-II but not by Runx2-I.
Materials and methods
Western blot analysis
Western blot analysis was performed using nuclear extracts from Cbfb−/−
calvarial cells and whole cell lysate from calvarial bones as previously described
(Yoshida et al., 2002). Proteins were resolved by SDS–10% polyacrylamide gel
electrophoresis. The blots were incubated first with monoclonal antibodies
against Runx2 and Cbfβ and goat polyclonal antibody against actin (Santa Cruz
Fig. 10. Real-time RT-PCR, BrdU incorporation, and TUNEL staining studies. (A) Real-time RT-PCR analysis. RNAwas extracted from upper limb bones of wild-
type (wt), Runx2-I transgenic (I), Runx2-II transgenic (II), Runx2-I/Cbfb transgenic (I/b), and Runx2-II/Cbfb transgenic (II/b) mice at 6 weeks of age. The levels of
Col1a1, osteopontin, osteocalcin, RANKL, and OPG mRNA expression were normalized against that of GAPDH. The level of GAPDH mRNA expression was set as
1000, and relative levels are shown. Mice (8–14) of each genotype were analyzed. (B) BrdU incorporation study. The proliferation index was defined as the percentage
of BrdU-positive osteoblasts out of the total number of osteoblasts. Mice (3–9) of each genotype were analyzed. (b) Cbfb transgenic mice. (C) TUNEL staining study.
The percentage of TUNEL-positive osteoblasts out of the total number of osteoblasts was calculated. Mice (4–9) of each genotype were analyzed. In panels A–C, data
are represented as mean ± SEM. *P < 0.05, **P < 0.005 vs. wild-type mice, as determined by one-way ANOVA.
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antibodies conjugated with horseradish peroxidase.
Reporter assay
The pSG5 (Stratagene, Tokyo, Japan), Runx2-I/pSG5, or Runx2-II/pSG5
and/or Cbfb/pcDNA3.1 vectors were cotransfected with p147mOG2-luc mouse
osteocalcin promoter construct (Harada et al., 1999) into calvarial cells that had
been derived from Cbfb−/− mice that carry the Cbfb transgene driven by the
Gata1 promoter using FuGENE6 (Roche Diagnostics, Mannheim, Germany)
(Yoshida et al., 2002). After 48 h, the luciferase activity of the cell lysate was
assayed using the Dual Luciferase Reporter Assay System (Promega, Madison,
WI) and a model TD20/20 luminometer (Turner BioSystems, Sunnyvale, CA).The transfection efficiency was normalized by quantifying renilla luciferase
activity using pRL-CMV (Promega, Tokyo, Japan).
EMSA
The same amounts of plasmid DNA encoding Runx2-I or Runx2-II (5 μg)
with or without plasmid DNA encoding Cbfβ (5 μg) were transfected to Cbfb−/−
calvarial cells. The total amount of DNA transfected was adjusted to 10 μg using
empty pSG5 vector. After 24 h, nuclear extracts were prepared and EMSAwas
performed as described previously (Yoshida et al., 2002). Competition was
carried out with either a 100-fold molar excess of unlabeled OSE2 oligonucleo-
tides or a 100-fold molar excess of mutated oligonucleotides (Thirunavukkarasu
et al., 1998). For supershift experiments, the antibody against Runx2 orCbfbwas
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nondenaturing polyacrylamide gels.
Generation of Runx2-I transgenic mice and Runx2-I/Cbfb and
Runx2-II/Cbfb double transgenic mice
To generate transgenic mice that overexpress Runx2-I in osteoblasts, we
inserted Runx2-I cDNA and the 2.3-kb osteoblast-specific promoter region of
mouse Col1a1 (Rossert et al., 1995) into the mammalian expression vector
pNASSβ (CLONTECH Laboratories Inc., Otsu, Japan). To generate transgenic
mice that overexpress Cbfb, we inserted the entire coding region of the Cbfβ2
isoform into the pcDNA3.1 vector (Invitrogen, Tokyo, Japan), which contains
the CMV promoter. The DNA fragments were injected into the pronuclei of
fertilized eggs from C57BL/6 × C3H F1 (B6C3H F1) mice. Transgene
integration and expression were identified by Southern blot and Northern blot
analyses, respectively. The transgenic lines were maintained in a B6C3H F1
background. Runx2-II transgenic mice were generated as previously described
(Liu et al., 2001). To generate Runx2-I/Cbfb and Runx2-II/Cbfb double trans-
genic mice, we mated Runx2-I transgenic mice and Runx2-II transgenic mice
with Cbfb transgenic mice, respectively. Prior to the study, all experiments were
reviewed and approved by the Animal Care and Use Committee of Nagasaki
University Graduate School of Biomedical Sciences.
Northern blot analysis and real-time RT-PCR
RNA extraction and Northern blot analysis were performed as previously
described (Inada et al., 1999). Real-time RT-PCR was performed as previously
described (Yoshida et al., 2004) using the following primers: Col1a1, 5′-CCC-
AAGGAAAAGAAGCACGTC-3′ and 5′-ACATTAGGCGCAGGAAGGTCA-
3′; osteopontin, 5′-CTCCAATCGTCCCTACAGTCG-3′ and 5′-CCAAGCTAT-
CACCTCGGCC-3′; osteocalcin, 5′-GCTGCCCTAAAGCCAAACTCT-3′ and
5′-AGAGGACAGGGAGGATCAAGTTC-3′; RANKL, 5′-CAAGCTCCGAG-
CTGGTGAAG-3′ and 5′-CCTGAACTTTGAAAGCCCCA-3′; OPG, 5′-AAG-
AGCAAACCTTCCAGCTGC-3′ and 5′-CACGCTGCTTTCACAGAGGTC-3′.
X-ray and pQCT analyses
Long bones were dissected from sacrificed mice at 6 weeks of age and
subjected to X-ray exposure using a Micro-FX1000 (Fuji Film Inc., Tokyo,
Japan). pQCT analysis was performed using femurs from 6- and 18-week-old
mice with XCT Research SA (Stratec Medizintechnick, Pforzheim, Germany).
The voxel size was 0.08 × 0.08 × 0.46 mm. The contour of the total bone was
automatically determined by the algorithm in the pQCT software. Cortical
parameters were obtained at the diaphysis and analyzed by ‘cortical mode 1’
using the threshold value, 690 mg/cm3.
Histological analyses
For histological analyses of the long bones, mice were sacrificed at 4, 6, or
8 weeks of age. To prepare sections for hematoxylin and eosin (H–E) staining,
immunohistochemistry, and in situ hybridization, we fixed mice in 4%
paraformaldehyde/0.1 M phosphate buffer, and we decalcified the long bones
in 0.5 M EDTA/10% glycerol buffer (pH7.5) and embedded in paraffin. Sections
(7 μm thick) were stained with H–E or subjected to immunohistochemical
analysis using anti-mouse osteopontin antibody (IBL Co., Ltd. Takasaki, Japan)
as previously described (Liu et al., 2001). In situ hybridization was performed
using probes for Col1a1, osteopontin, and osteocalcin as described previously
(Inada et al., 1999). For assessment of dynamic histomorphometric indices, we
injected mice twice with calcein at a dose of 0.16 mg/10 g body weight at 5 days
and at 1 day before sacrifice at 6 weeks of age. The long bones were fixed with
70% ethanol, and the undecalcified bones were embedded in glycolmethacry-
late. Three-micrometer longitudinal sections of the distal parts of femurs were
stained with toluidine blue and analyzed using a semiautomated system (Bone
Histomorphometric System, System Supply, Nagano, Japan). The nomencla-
ture, symbols, and units used are those that are recommended by the Nomen-
clature Committee of the American Society for Bone and Mineral Research
(Parfitt et al., 1987). Some of the sections were stained with TRAP.BrdU incorporation study and TUNEL staining
Two-week-old mice were injected intraperitoneally with 100 μg BrdU/g
body weight and sacrificed 1 h later. Decalcified sections of the tibiae were
prepared and stained with the BrdU staining kit (Zymed Lab, South San
Francisco, CA). The number of BrdU-positive cells and the total number of
osteoblasts in the primary spongiosa were counted. TUNEL staining was
performed with the ApopTag® system (Intergen, New York, NY) using
decalcified sections of the tibiae from 2-week-old mice. The number of TUNEL-
positive cells and the total number of osteoblasts in the primary spongiosa were
counted.Acknowledgments
We thank B. de Crombrugghe for Col1a1 promoter; Y. Ito for
Runx2 and Cbfβ antibodies; K. Nonaka (Elk Corporation) for
pQCTanalysis; K. Nakamura, N. Komatsu, and K. Kawagoe for
maintaining mouse colonies; and A. Kakiya for secretarial
assistance. This work was supported by The Naito Foundation
and grants from the Ministry of Education, Culture, Sports,
Science, and Technology, Japan.References
Alliston, T., Choy, L., Ducy, P., Karsenty, G., Derynck, R., 2001. TGF-β-
induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin
expression and inhibits osteoblast differentiation. EMBO J. 20, 2254–2272.
Aubin, E.J., Triffitt, T.J., 2002. Mesenchymal stem cells and osteoblast diffe-
rentiation. In: Bilezikian, J.P., Raisz, L.G., Rodan, G.A. (Eds.), Principles of
Bone Biology. Academic Press, pp. 115–126.
Banerjee, C., Hiebert, S.W., Stein, J.L., Lian, J.B., Stein, G.S., 1996. An AML-1
consensus sequence binds an osteoblast-specific complex and transcription-
ally activates the osteocalcin gene. Proc. Natl. Acad. Sci. U. S. A. 93,
4968–4973.
Banerjee, C., Javed, A., Choi, J.Y., Green, J., Rosen, V., van Wijnen, A.J., Stein,
J.L., Lian, J.B., Stein, G.S., 2001. Differential regulation of the two principal
Runx2/Cbfa1 N-terminal isoforms in response to bone morphogenetic
protein-2 during development of the osteoblast phenotype. Endocrinology
142, 4026–4039.
Banerjee, C., McCabe, L.R., Choi, J.Y., Hiebert, S.W., Stein, J.L., Stein, G.S.,
Lian, J.B., 1997. Runt homology domain proteins in osteoblast differen-
tiation: AML3/CBFA1 is a major component of a bone-specific complex.
J. Cell. Biochem. 66, 1–8.
Choi, K.Y., Lee, S.W., Park, M.H., Bae, Y.C., Shin, H.I., Nam, S., Kim, Y.J.,
Kim, H.J., Ryoo, H.M., 2002. Spatio-temporal expression patterns of Runx2
isoforms in early skeletogenesis. Exp. Mol. Med. 34, 426–433.
Ducy, P., Karsenty, G., 1995. Two distinct osteoblast-specific cis-acting
elements control expression of a mouse osteocalcin gene. Mol. Cell. Biol.
15, 1858–1869.
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L., Karsenty, G., 1997. Osf2/Cbfa1 a
transcriptional activator of osteoblast differentiation. Cell 89, 747–754.
Ducy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy, V., Amling,
M., Karsenty, G., 1999. A Cbfa1-dependent genetic pathway controls bone
formation beyond embryonic development. Genes Dev. 13, 1025–1036.
Enomoto, H., Enomoto-Iwamoto, M., Iwamoto, M., Nomura, S., Himeno, M.,
Kitamura, Y., Kishimoto, T., Komori, T., 2000. Cbfa1 is a positive regulatory
factor in chondrocyte maturation. J. Biol. Chem. 275, 8695–8702.
Enomoto, H., Shiojiri, S., Hoshi, K., Furuichi, T., Fukuyama, R., Yoshida,
C.A., Kanatani, N., Nakamura, R., Mizuno, A., Zanma, A., Yano, K.,
Yasuda, H., Higashio, K., Takada, K., Komori, T., 2003. Induction of
osteoclast differentiation by Runx2 through receptor activator of nuclear
factor-(B Ligand (RANKL) and osteoprotegerin regulation and partial
rescue of osteoclastogenesis in Runx2−/− mice by RANKL transgene. J.
Biol. Chem. 278, 23971–23977.
61N. Kanatani et al. / Developmental Biology 296 (2006) 48–61Fujiwara, M., Tagashira, S., Harada, H., Ogawa, S., Katsumata, T.,
Nakatsuka, M., Komori, T., Takada, H., 1999. Isolation and characteriza-
tion of the distal promoter region of mouse Cbfa1. Biochim. Biophys.
Acta 1446, 265–272.
Geoffroy, V., Ducy, P., Karsenty, G., 1995. A PEBP2α/AML-1-related factor
increases osteocalcin promoter activity through its binding to an osteoblast-
specific cis-acting element. J. Biol. Chem. 270, 30973–30979.
Geoffroy, V., Kneissel, M., Fournier, B., Boyde, A., Matthias, P., 2002. High
bone resorption in adult aging transgenicmice overexpressing cbfa1/runx2 in
cells of the osteoblastic lineage. Mol. Cell. Biol. 22, 6222–6233.
Harada, H., Tagashira, S., Fujiwara, M., Ogawa, S., Katsumata, T., Yamaguchi,
A., Komori, T., Nakatsuka, M., 1999. Cbfa1 isoforms exert functional
differences in osteoblast differentiation. J. Biol. Chem. 274, 6972–6978.
Huang, G., Shigesada, K., Ito, K., Wee, H.J., Yokomizo, T., Ito, Y., 2001.
Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-
proteasome-mediated degradation. EMBO J. 20, 723–733.
Inada, M., Yasui, T., Nomura, S., Miyake, S., Deguchi, K., Himeno, M., Sato,
M., Yamagiwa, H., Kimura, T., Yasui, N., Ochi, T., Endo, N., Kitamura, Y.,
Kishimoto, T., Komori, T., 1999. Maturational disturbance of chondrocytes
in Cbfa1-deficient mice. Dev. Dyn. 214, 279–290.
Javed, A., Gutierrez, S.,Montecino,M., vanWijnen, A.J., Stein, J.L., Stein, G.S.,
Lian, J.B., 1999.Multiple Cbfa/AML sites in the rat osteocalcin promoter are
required for basal and vitamin D-responsive transcription and contribute to
chromatin organization. Mol. Cell. Biol. 19, 7491–7500.
Javed, A., Barnes, G.L., Jasanya, B.O., Stein, J.L., Gerstenfeld, L., Lian, J.B.,
Stein, G.S., 2001. runt Homology domain transcription factors (Runx, Cbfa,
and AML) mediate repression of the bone sialoprotein promoter: evidence
for promoter context-dependent activity of Cbfa proteins. Mol. Cell. Biol.
21, 2891–2905.
Kern, B., Shen, J., Starbuck, M., Karsenty, G., 2001. Cbfa1 contributes to the
osteoblast-specific expression of type I collagen genes. J. Biol. Chem. 276,
7101–7107.
Kobayashi, H., Gao, Y., Ueta, C., Yamaguchi, A., Komori, T., 2000. Multi-
lineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem.
Biophys. Res. Commun. 273, 630–636.
Komori, T., 2005. Regulation of skeletal development by the Runx family of
transcription factors. J. Cell. Biochem. 95, 445–453.
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K.,
Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., Sato, M., Okamoto, R.,
Kitamura, Y., Yoshiki, S., Kishimoto, T., 1997. Targeted disruption of Cbfa1
results in a complete lack of bone formation owing to maturational arrest of
osteoblasts. Cell 89, 755–764.
Kundu, M., Javed, A., Jeon, J.P., Horner, A., Shum, L., Eckhaus, M., Muenke,
M., Lian, J.B., Yang, Y., Nuckolls, G.H., Stein, G.S., Liu, P.P., 2002. Cbfβ
interacts with Runx2 and has a critical role in bone development. Nat. Genet.
32, 639–644.
Lee, K.S., Kim, H.J., Li, Q.L., Chi, X.Z., Ueta, C., Komori, T., Wozney, J.M.,
Kim, E.G., Choi, J.Y., Ryoo, H.M., Bae, S.C., 2000. Runx2 is a common
target of transforming growth factor β1 and bone morphogenetic protein 2,
and cooperation between Runx2 and Smad5 induces osteoblast-specific
gene expression in the pluripotent mesenchymal precursor cell line C2C12.
Mol. Cell. Biol. 20, 8783–8792.
Lengner, C.J., Drissi, H., Choi, J.Y., van Wijnen, A.J., Stein, J.L., Stein, G.S.,
Lian, J.B., 2002. Activation of the bone-related Runx2/Cbfa1 promoter in
mesenchymal condensations and developing chondrocytes of the axial
skeleton. Mech. Dev. 114, 167–170.
Liu, W., Toyosawa, S., Furuichi, T., Kanatani, N., Yoshida, C., Liu, Y., Himeno,
M., Narai, S., Yamaguchi, A., Komori, T., 2001. Overexpression of Cbfa1 in
osteoblasts inhibits osteoblast maturation and causes osteopenia with
multiple fractures. J. Cell Biol. 155, 157–166.
Merriman, H.L., van Wijnen, A.J., Hiebert, S., Bidwell, J.P., Fey, E., Lian, J.,
Stein, J., Stein, G.S., 1995. The tissue-specific nuclear matrix protein, NMP-
2, is a member of the AML/CBF/PEBP2/Runt domain transcription factor
family: interaction with the osteocalcin gene promoter. Biochemistry 34,
13125–13132.
Miller, J., Horner, A., Stacy, T., Lowrey, C., Lian, J.B., Stein, G., Nuckolls, G.H.,
Speck, N.A., 2002. The core-binding factor β subunit is required for bone
formation and hematopoietic maturation. Nat. Genet. 32, 645–649.Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M.,
Shigesada, K., Ito, Y., 1993a. PEBP2/PEA2 represents a family of
transcription factor homologous to the products of the Drosophila runt
gene and the human AML1 gene. Proc. Natl. Acad. Sci. U. S. A. 90,
6859–6863.
Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito,
Y., Shigesada, K., 1993b. Molecular cloning and characterization of
PEBP2β, the heterodimeric partner of a novel Drosophila runt-related
DNA binding protein PEBP2α. Virology 194, 314–331.
Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R.,
Stamp, G.W., Beddington, R.S., Mundlos, S., Olsen, B.R., Selby, P.B.,
Owen, M.J., 1997. Cbfa1, a candidate gene for cleidocranial dysplasia
syndrome, is essential for osteoblast differentiation and bone development.
Cell 89, 765–771.
Parfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H., Meunier,
P.J., Ott, S.M., Recker, R.R., 1987. Bone histomorphometry: standardization
of nomenclature, symbols, and units. J. Bone Miner. Res. 2, 595–610.
Park, M.H., Shin, H.I., Choi, J.Y., Nam, S.H., Kim, Y.J., Kim, H.J., Ryoo, H.M.,
2001. Differential expression patterns of Runx2 isoforms in cranial suture
morphogenesis. J. Bone Miner. Res. 16, 885–892.
Rossert, J., Eberspaecher, H., de Crombrugghe, B., 1995. Separate cis-acting
DNA elements of the mouse pro-α1(I) collagen promoter direct expression
of reporter genes to different type I collagen-producing cells in transgenic
mice. J. Cell Biol. 129, 1421–1432.
Sasaki, K., Yagi, H., Bronson, R.T., Tominaga, K., Matsunashi, T., Deguchi, K.,
Tani, Y., Kishimoto, T., Komori, T., 1996. Absence of fetal liver hema-
topoiesis in mice deficient in transcriptional coactivator core binding factor
β. Proc. Natl. Acad. Sci. U. S. A. 93, 12359–12363.
Sato, M., Morii, E., Komori, T., Kawahata, H., Sugimoto, M., Terai, K., Shimizu,
H., Yasui, T., Ogihara, H., Yasui, N., Ochi, T., Kitamura, Y., Ito, Y., Nomura,
S., 1998. Transcriptional regulation of osteopontin gene in vivo by PEBP2αA/
CBFA1 and ETS1 in the skeletal tissues. Oncogene 17, 1517–1525.
Stewart, M., Terry, A., Hu, M., O'hara, M., Blyth, K., Baxter, E., Cameron, E.,
Onions, D.E., Neil, J.C., 1997. Proviral insertions induce the expression of
bone-specific isoforms of PEBP2aA (CBFA1): evidence for a new myc
collaborating oncogene. Proc. Natl. Acad. Sci. U. S. A. 94, 8646–8651.
Thirunavukkarasu, K., Mahajan, M., McLarren, K.W., Stifani, S., Karsenty, G.,
1998. Two domains unique to osteoblast-specific transcription factor Osf2/
Cbfa1 contribute to its transactivation function and its inability to
heterodimerize with Cbfb. Mol. Cell. Biol. 18, 4197–4208.
Ueta, C., Iwamoto, M., Kanatani, N., Yoshida, C., Liu, Y., Enomoto-Iwamoto,
M., Ohmori, T., Enomoto, H., Nakata, K., Takada, K., Kurisu, K., Komori, T.,
2001. Skeletal malformations caused by overexpression of Cbfa1 or its
dominant negative form in chondrocytes. J. Cell Biol. 153, 87–100.
Wang, Q., Stacy, T., Miller, J.D., Lewis, A.F., Gu, T.L., Huang, X., Bushweller, J.
H., Bories, J.C., Alt, F.W., Ryan, G., Liu, P.P., Wynshaw-Boris, A., Binder,
M.,Marín-Padilla, M., Sharp, A.H., Speck, N.A., 1996. The CBFβ subunit is
essential for CBFα2 (AML1) function in vivo. Cell 87, 697–708.
Xiao, Z.S., Hinson, T.K., Quarles, L.D., 1999. Cbfa1 isoform overexpression
upregulates osteocalcin gene expression in non-osteoblastic and pre-
osteoblastic cells. J. Cell. Biochem. 74, 596–605.
Xiao, Z.S., Hjelmeland, A.B., Quarles, L.D., 2004. Selective deficiency of the
“bone-related” Runx2-II unexpectedly preserves osteoblast-mediated skele-
togenesis. J. Biol. Chem. 279, 20307–20313.
Xiao, Z.S., Awad, H.A., Liu, S., Mahlios, J., Zhang, S., Guilak, F., Mayo, M.S.,
Quarles, L.D., 2005. Selective Runx2-II deficiency leads to low-turnover
osteopenia in adult mice. Dev. Biol. 283, 345–356.
Yoshida, C.A., Furuichi, T., Fujita, T., Fukuyama, R., Kanatani, N., Kobayashi, S.,
Satake, M., Takada, K., Komori, T., 2002. Core-binding factor β interacts with
Runx2 and is required for skeletal development. Nat. Genet. 32, 633–638.
Yoshida, C.A., Yamamoto, H., Fujita, T., Furuichi, T., Ito, K., Inoue, K., Yamana,
K., Zanma, A., Takada, K., Ito, Y., Komori, T., 2004. Runx2 and Runx3 are
essential for chondrocyte maturation, and Runx2 regulates limb growth
through induction of Indian hedgehog. Genes Dev. 18, 952–963.
Zaidi, S.K., Javed, A., Choi, J.Y., van Wijnen, A.J., Stein, J.L., Lian, J.B., Stein,
G.S., 2001. A specific targeting signal directs Runx2/Cbfa1 to subnuclear
domains and contributes to transactivation of the osteocalcin gene. J. Cell
Sci. 114, 3093–3102.
